Candel Therapeutics (CADL) vs OmniAb (OABI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
OmniAb (OABI) has outperformed Candel Therapeutics (CADL) over the past year, gaining 163.2% versus a gain of 51.8%. Over five years, CADL leads with a +1.1% price change compared with -52.0% for OABI. Candel Therapeutics is the larger company by market cap ($760.6 million vs $696.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CADL | OABI |
|---|---|---|
| Share price | $9.94 | $4.79 |
| Market cap | $760.59M | $696.42M |
| 1-day change | +2.90% | +2.79% |
| YTD return | +75.93% | +158.92% |
| 1-year return | +51.76% | +163.19% |
| 5-year return | +1.12% | -51.96% |
| EPS (TTM) | $-1.50 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.00 | $5.43 |
| 52-week low | $4.35 | $1.30 |
| Distance from 52-week high | -29.00% | -11.79% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +118.81% | +73.90% |
| Average volume | 1.21M | 1.47M |
| Shares outstanding | 76.52M | 145.39M |
| Employees | 55 | 89 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OABI has outperformed CADL by 111.4 percentage points over the past year.
About Candel Therapeutics
CADL stock →Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 55 employees
About OmniAb
OABI stock →OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 89 employees
CADL vs OABI FAQ
Which is bigger, Candel Therapeutics or OmniAb?
Candel Therapeutics (CADL) is larger, with a market capitalization of $760.59M compared with $696.42M for OmniAb (OABI).
Which stock has performed better over the past year, CADL or OABI?
OABI returned +163.19% over the past 12 months, compared with +51.76% for CADL (price return, excluding dividends). Past performance does not predict future results.
Are Candel Therapeutics and OmniAb in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Candel Therapeutics and Biotechnology: Commercial Physical & Biological Resarch for OmniAb.